Janssen Research & Development, LLC recently submitted a supplemental new drug application to the FDA for abiraterone acetate (ZYTIGA) intended to extend the use of abiraterone administered with prednisone to include the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and before chemotherapy.
The investigational agent radium-223 dichloride significantly increased overall survival in patients with castration-resistant prostate cancer with bone metastases, updated results of a recent phase III trial showed.
Heddy Hubbard, PhD, MPH, RN, has been named associate executive director of science and quality at the AUA.
Johnson & Johnson said its Ethicon division has informed the FDA and other regulatory bodies worldwide that it has decided to discontinue certain Gynecare vaginal mesh implants around the world.
The Urgent PC Neuromodulation System (Uroplasty, Inc., Minneapolis) demonstrated sustained safety and efficacy over 24 months in patients with overactive bladder, the authors of a recent study reported.
The American Medical Association has called on the U.S. Preventive Services Task Force (USPSTF) to incorporate consultation from specialists when preparing guidelines.
New data have added to previous evidence that the use of pioglitazone (Actos) appears to be associated with an increased risk of incident bladder cancer among patients with type 2 diabetes, Canadian researchers recently reported.
Men undergoing robot-assisted surgery for prostate cancer should look for a physician who has performed at least 1,000 surgeries and who actively seeks to improve and enhance his surgical skills to help ensure a successful post-surgery recovery of erectile function, according to a recent study.
Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen deprivation therapy than on intermittent therapy, report SWOG researchers.
The American Society for Radiation Oncology expressed disappointment in the U.S. Preventive Services Task Force's (USPSTF) final recommendations against the use of PSA-based screening for prostate cancer and strongly cautions against a blanket no-testing policy.
The 2012 AUA annual meeting in Atlanta saw the debut of new practice guidelines for overactive bladder, hematuria, vasectomy, and urodynamics.
In an initial decision, a chief administrative law judge upheld a Federal Trade Commission complaint and ruled that POM Wonderful LLC and related parties violated federal law by making deceptive claims in some advertisements that their POM Wonderful 100% Pomegranate Juice and POMx supplements would treat, prevent, or reduce the risk of heart disease, prostate cancer, and erectile dysfunction.
The number of Americans suffering from kidney stones between 2007 and 2010 nearly doubled from 1994, according to a study by researchers at UCLA and the RAND Corp.
Six months of treatment with the targeted androgen biosynthesis inhibitor abiraterone (ZYTIGA), in addition to standard hormonal therapy before prostatectomy, eliminated or nearly eliminated cancer in one-third of men with localized high-risk prostate cancer, a recent study found.
Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine PSA screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a recent survey.
In a survey conducted last month, 90.5% of U.S. oncologists reported experiencing shortages of key cancer drugs in their practices, including drugs for prostate cancer.
In patients undergoing partial nephrectomy, warm ischemia time greater than 25 minutes is associated with greater loss of kidney function, according to a recent report.
A common variant on chromosome 14 confers a 19% lower risk of bladder cancer, in part because of the variant's association with increased length of telomeres.
Elevated pretreatment androgen levels correlate with significantly better overall survival in men with castration-resistant prostate cancer, regardless of treatment, a recent post hoc analysis of a large randomized trial showed.
Recent studies suggest that nocturia has many etiologies, including urologic, metabolic, and perhaps most important, behavorial.
Drugs and devices in the pipeline from GTX Inc., Auxilium Pharmaceuticals, Inc., Tengion Inc., OncoGenex, and Tokai Pharmaceuticals, Inc.
Practice complication rates following surgical treatment for BPH are higher than indicated by clinical trials, according to a recent study.
Phosphodiesterase type-5 inhibitors are safe and effective, alone or in combination with alpha-blockers, against lower urinary tract symptoms secondary to BPH, according to a recent systematic review and meta-analysis.
New products and services from ProUroCare, Touch of Life Technologies, and MDxHealth.
Three fourths of patients with refractory urothelial cancer had stable disease or better response when treated with the angiogenesis inhibitor pazopanib (Votrient), Italian researchers recently reported.
Ureteroscopy has overtaken extracorporeal shock wave lithotripsy as the treatment of choice for kidney stones, Canadian researchers recently reported.
Academic urology can provide an array of opportunities.
There are many aspects of the business of medicine that are difficult to influence. Here are some ways that you can have some control.
Physician opinion is divided almost evenly on the question of whether to prescribe phosphodiesterase type-5 inhibitors to patients for non-medical indications, a survey of Israeli doctors showed.
